GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SanBio Co Ltd (OTCPK:SNBIF) » Definitions » EV-to-EBITDA

SanBio Co (SanBio Co) EV-to-EBITDA : -10.21 (As of May. 24, 2024)


View and export this data going back to 2015. Start your Free Trial

What is SanBio Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, SanBio Co's enterprise value is $185.24 Mil. SanBio Co's EBITDA for the trailing twelve months (TTM) ended in Jan. 2024 was $-18.15 Mil. Therefore, SanBio Co's EV-to-EBITDA for today is -10.21.

The historical rank and industry rank for SanBio Co's EV-to-EBITDA or its related term are showing as below:

SNBIF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -243.87   Med: -19.86   Max: -2.27
Current: -11

During the past 11 years, the highest EV-to-EBITDA of SanBio Co was -2.27. The lowest was -243.87. And the median was -19.86.

SNBIF's EV-to-EBITDA is ranked worse than
100% of 446 companies
in the Biotechnology industry
Industry Median: 10.33 vs SNBIF: -11.00

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-24), SanBio Co's stock price is $3.85. SanBio Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 was $-0.289. Therefore, SanBio Co's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


SanBio Co EV-to-EBITDA Historical Data

The historical data trend for SanBio Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SanBio Co EV-to-EBITDA Chart

SanBio Co Annual Data
Trend Jan15 Jan16 Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -21.49 -24.69 -12.33 -9.01 -13.77

SanBio Co Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.01 -5.58 -6.10 -3.55 -13.77

Competitive Comparison of SanBio Co's EV-to-EBITDA

For the Biotechnology subindustry, SanBio Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SanBio Co's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SanBio Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where SanBio Co's EV-to-EBITDA falls into.



SanBio Co EV-to-EBITDA Calculation

SanBio Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=185.235/-18.147
=-10.21

SanBio Co's current Enterprise Value is $185.24 Mil.
SanBio Co's EBITDA for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-18.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SanBio Co  (OTCPK:SNBIF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

SanBio Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.85/-0.289
=At Loss

SanBio Co's share price for today is $3.85.
SanBio Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.289.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


SanBio Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of SanBio Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


SanBio Co (SanBio Co) Business Description

Traded in Other Exchanges
Address
8-1 Street Luke Tower 32nd Floor, Akashi-cho, Chuo-ku, Tokyo, JPN, 104-0044
SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.

SanBio Co (SanBio Co) Headlines

From GuruFocus

Q2 2019 SanBio Co Ltd Earnings Call Transcript

By GuruFocus Research 02-15-2024

Full Year 2023 SanBio Co Ltd Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q2 2022 SanBio Co Ltd Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q2 2021 SanBio Co Ltd Earnings Call Transcript

By GuruFocus Research 02-15-2024

Full Year 2021 SanBio Co Ltd Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q2 2024 SanBio Co Ltd Earnings Presentation Transcript

By GuruFocus Research 02-15-2024